Prime Medicine
Keith Mattar has a diverse work experience in the fields of informatics, analytics, and data engineering. Keith is currently working as an Associate Director of Informatics, Analytics, and Data Engineering at Prime Medicine, Inc. Keith'sresponsibilities in this role are not specified.
Prior to their current position, Keith worked at Rubius Therapeutics from 2019 to 2022, where they held the position of Associate Director/Senior Manager of Data Systems and Analytics. In this role, they managed a team responsible for the deployment, administration, and development of various informatics platforms. Keith also managed multiple enterprise-level projects and maintained relationships with external partners and vendors.
Before Rubius Therapeutics, Keith worked at Momenta Pharmaceuticals from 2012 to 2019. Keith initially served as an Application Support Specialist, responsible for administering and providing technical support for various informatics platforms used by the company. Later, they took on the role of Senior Data Associate, where they were in charge of sample log-in and verification, data integrity checks, and storing test results.
Keith's earlier work experience includes a role as an Analyst at Thielsch Engineering from 2011 to 2012 and a position as a Laboratory Technician at GZA GeoEnvironmental from 2010 to 2011.
Overall, Keith has a strong background in informatics, analytics, and data engineering, with experience in managing teams, handling enterprise-level projects, and administering various informatics platforms.
Keith Mattar earned a Bachelor of Science (B.S.) degree in Biology, General from the University of Massachusetts Amherst in 2009.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.